Coronary Risk Assessment by Point-Based vs. Equation-Based Framingham Models: Significant Implications for Clinical Care by Gordon, William J. et al.
ORIGINAL RESEARCH
Coronary Risk Assessment by Point-Based vs. Equation-Based
Framingham Models: Significant Implications for Clinical Care
William J. Gordon, BA
1,2, Jesse M. Polansky, MD, MPH
3, W. John Boscardin, PhD
4,5,
Kathy Z. Fung, MS
4,6, and Michael A. Steinman, MD
2,4,6
1 Weill Cornell Medical College, New York, NY, USA;
2 Medical Student Training in Aging Research Program, San Francisco, CA, USA;
3 Centers
for Medicare and Medicaid Services, Baltimore, MD, USA;
4Division of Geriatrics, University of California, San Francisco, CA, USA;
5Department
of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA;
6 San Francisco VA Medical Center, San Francisco, CA, USA.
BACKGROUND: US cholesterol guidelines use original
and simplified versions of the Framingham model to
estimate future coronary risk and thereby classify
patients into risk groups with different treatment
strategies. We sought to compare risk estimates and
risk group classification generated by the original,
complex Framingham model and the simplified, point-
based version.
METHODS: We assessed 2,543 subjects age 20–79 from
the 2001–2006 National Health and Nutrition Exami-
nation Surveys (NHANES) for whom Adult Treatment
Panel III (ATP-III) guidelines recommend formal risk
stratification. For each subject, we calculated the 10-
year risk of major coronary events using the original
and point-based Framingham models, and then com-
pared differences in these risk estimates and whether
these differences would place subjects into different
ATP-III risk groups (<10% risk, 10–20% risk, or >20%
risk). Using standard procedures, all analyses were
adjusted for survey weights, clustering, and stratifica-
tion to make our results nationally representative.
RESULTS: Among 39 million eligible adults, the original
Framinghammodelcategorized71%ofsubjectsashaving
“moderate” risk (<10% risk of a major coronary event in
the next 10 years), 22% as having “moderately high” (10–
20%)risk,and7%ashaving“high”(>20%)risk.Estimates
of coronary risk by the original and point-based models
often differed substantially. The point-based system
classified 15% of adults (5.7 million) into different risk
groups than the original model, with 10% (3.9 million)
misclassified into higher risk groups and 5% (1.8 million)
into lower risk groups, for a net impact of classifying 2.1
million adults into higher risk groups. These risk group
misclassifications would impact guideline-recommended
drug treatment strategies for25–46% ofaffected subjects.
Patterns of misclassifications varied significantly by
gender, age, and underlying CHD risk.
CONCLUSIONS: Compared to the original Framing-
ham model, the point-based version misclassifies
millions of Americans into risk groups for which
guidelines recommend different treatment strategies.
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INTRODUCTION
National cholesterol guidelines use a “Framingham model” to
calculate a person’s 10-year risk of myocardial infarction or
coronary death. Based on this risk, patients are categorized
into different risk groups, which are used to guide treatment
decisions.
1 The Framingham model is a complex mathematical
equation. To enable use in settings without calculators or
computers, the formula for calculating risk was simplified into
a point-based or “score sheet” system.
2
Both the original and point-based versions of the Framing-
ham model are endorsed by the National Cholesterol Educa-
tion Project’s Adult Treatment Panel III (ATP III) guidelines.
1,3
However, it is possible that the simplified point-based system
may lead to less accurate risk estimates and potentially
different treatment recommendations. The original system
derives risk estimates using Cox regression models based on
patient age, total and HDL cholesterol, systolic blood pressure,
treatment for hypertension, and smoking status. For example,
basedonthe originalFraminghammodelequation,a 45-year-old
male smoker with total cholesterol 170 mg/dl, HDL 38 mg/dl,
andsystolicbloodpressureof125mmHgnotonantihypertensive
treatment would be calculated to have a 7% risk of myocardial
infarction or death over 10 years. In contrast, the point-based
system assigns each risk factor level an integer number. These
riskfactorvaluesare summedtoderivea score,and then the risk
for that score is determined from a look-up table. For example,
this same patient above would get 3 points for being age
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114545–49 years,5 pointsfor smoking, andsoforth for a total score of
13 points, which corresponds to a 12% risk of a major coronary
event over the next 10 years.
The proliferation of computers and personal digital
assistants (PDAs) in clinical medicine enables easy imple-
mentation of the original, mathematically complex Framing-
ham model at the point of care. However, the point-based
system has remained in widespread use in both clinical
practice and research, including widespread application in
computerized risk prediction tools.
4–8 Given that approxi-
mately 36 million persons in the US are eligible for lipid-
lowering therapy, differences in classification could result in
millions of persons receiving different lipid-lowering therapy
depending on which model is used.
9,10 In this study, we
used nationally representative data to compare differences
in predicted risk between the original and point-based
Framingham calculations and to determine the degree to
which the point-based system stratifies patients into differ-
ent risk groups.
METHODS
Data were obtained from the 2001-2006 waves of the National
Health and Nutrition Examination Survey (NHANES). Respon-
dents were selected and their data weighted to be representative of
the non-institutionalized US population.
11
Under ATP III guidelines, patients with known coronary heart
disease (CHD) or risk equivalents are considered high-risk (>20%
10-year risk). Patients with 0–1r i s kf a c t o r sa r ec o n s i d e r e dt ob e
low risk. Patients with two or more risk factors but no known
CHD or risk equivalents are placed in an indeterminate risk
group. The Framingham risk model is used on patients in this
indeterminate group to assess whether they are at “moderate”
(<10%), “moderately high” (10-20%), or “high” (>20%) risk of
myocardial infarction or coronary death in the next 10 years
(Fig. 1).
1
Our analyses focused on adults age 20–79 in this indetermi-
nate group (the Framingham models are not adapted to people
over age 79 years). We excluded the 11% of patients in this group
who reported taking lipid-lowering therapy, since the Framing-
ham models and risk stratification algorithms are not designed
to predict risk in this population.
We used self-report data from NHANES to exclude subjects
with CHD or risk equivalents, including myocardial infarction,
angina pectoris, diabetes mellitus, or stroke. Next, we summed
the number of risk factors for each subject including current
cigarette use, hypertension (defined by self-report or documented
blood pressure ≥140/≥90 mmHg), low HDL (<40 mg/dl), family
history of CHD (history of heart attack or angina before age
50 years in close biological relatives), and age (male >45 years
o l d ,f e m a l e> 5 5y e a r so l d ) .S u b j e c t sw i t hH D L> 6 0m g / d lh a do n e
point subtracted from their risk factor sum. Subjects with two or
more risk factors formed our analytic cohort.
We used the multiple imputation by chained equations
procedure for the 2005–2006 wave of NHANES to account for
the approximately 11% of eligible subjects who had incomplete
data, mostly due to absent blood pressures and laboratory
values for total and HDL cholesterol.
12,13 Our multiple imputa-
tion analysis results were very similar to those obtained
analyzing only subjects with complete data. We thus conducted
our main analyses for all three waves on subjects with complete
data.
Analyses
As the Framingham models are gender specific, we split our
cohort into male and female groups. Using formulas published
on the Framingham Heart Study website, for each subject we
calculated the predicted 10-year risk of hard CHD events using
the original and point-based models.
14 Next, we determined
which risk group each person in our cohort would be placed in
under the original model and calculated the number of people
reclassified into a higher or lower risk group by the point-
based system. We term this shift between risk groups “mis-
classification,” insofar as such patients are misclassified
relative to the original Framingham model. We evaluated
differences in risk classification using kappa statistics and
compared the estimated probabilities of misclassification into
lower or higher ATP III risk groups using multinomial models.
Finally, among patients misclassified by the point-based
system, we determined whether this misclassification would
impact guideline-based drug treatment recommendations. For
this analysis, we used LDL levels, which were collected on
NHANES participants examined in the morning (1,079 of our
2,543 subjects). Among misclassified subjects, we determined
if LDL levels were above the threshold for starting drug therapy
given their risk group determined by one model, but below the
threshold for starting drug therapy given the risk group
determined by the other model.
All analyses were conducted using Stata 10.1 (StataCorp,
College Station, TX) and were adjusted for subject weights and
clustering effects using standard methods recommended by
NHANES to make our results nationally representative.
RESULTS
Among 11,967 subjects aged 20–79 years, 1,898 had known
CHD or risk equivalents, 7,080 had 0 or 1 CHD risk factors,
and 446 were taking a lipid-lowering drug. The remaining
2,543 subjects, representing 39 million adults, formed our
analytic cohort (Fig. 1). About one third of our analytic cohort
was female, with a median age of 48 years, and three-quarters
were white (Table 1). Half were cigarette smokers, 56% had
hypertension, 30% had a family history of CHD, 46% had HDL
cholesterol <40 mg/dl, and slightly under half had LDL
cholesterol levels of 130 mg/dl or greater. As calculated by
the original model, 71% had a “moderate” risk of a major
coronary event in the next 10 years (including 48% with <5%
risk and 23% with 5–9% risk), 22% were at “moderately high”
risk, and 7% were at “high” risk (data not shown in Table).
Figure 2 shows the ATP III risk groups that patients would
be assigned to had their risk been calculated by the original
model vs. the point-based model. Compared with the original
model, the point-based system misclassified 15% of subjects
(95% CI, 13%–16%) into different ATP III risk groups,
corresponding to 5.7 million people. Kappa for agreement in
risk group stratification was 0.69. Misclassification dispropor-
tionately shifted patients into higher risk groups (P<0.001),
with 10% (95% CI 9%–12%; 3.9 million people) misclassified
into higher risk groups and 5% (95% CI, 4%–6%; 1.8 million
people) into lower risk groups. The majority of upward
classification originated among patients in the lowest risk
group. The largest source of downward classification was
1146 Gordon et al.: Point-Based vs. Equation-Based Framingham Models JGIMamong subjects placed in the “high risk” group by the original
Framingham model, of whom 45% (1.2 million of 2.7 million)
were misclassified as “moderately high risk” or “moderate risk”
under the point-based system.
Patterns ofmisclassificationvariedsignificantly by genderand
age. Overall, 17% of men (95% CI, 15%–19%; 4.3 million) and
11% of women (95% CI, 9%–14%; 1.4 million) were
misclassified (P=0.003 for difference between genders).
Among those misclassified, 64% of men (95% CI, 58%–
70%) and 80% of women (95% CI, 72%–87%) were shifted
into higher risk groups by the point-based system. Results
also varied by age groups. Misclassification affected 7% of
people aged 20–44 years (95% CI, 5%-9%; 1.0 million), 17%
aged 45–64 years (95% CI, 15%–20%; 3.2 million), and 27%
aged 65–79 years (95% CI, 23%–30%, 1.5 million; P<0.001
for difference between age groups). This variation in
misclassification patterns may in part be attributable to
underlying differences in CHD risks between age and sex
groups.
Next, we compared point estimates of risk generated by the
original and point-based models. On average, the point-based
system generated higher risk estimates than the original
model by a mean of 0.6% (95% CI, 0.5%–0.8%; SD 3.3%) in
men and 0.4% (95% CI, 0.2%–0.6%, SD 2.5%) in women
(Table 2 and e-Appendix). Differences between the models
were often substantial for individual patients, and the
magnitude of differences grew as risk increased. For example,
the median absolute risk difference for men at “moderate”
risk (predicted by the original model) was 1.0% [interquartile
range (IQR) 0.5%–1.8%), increasing to a mean absolute risk
difference of 3.6% (IQR 1.8%–6.4%) for those in the “high
risk” group. Differences of more than 5% between the original
and point-based models were common at higher levels of risk,
occurring in 26% of subjects (95% CI, 23%–30%) who had
Step 1 
Does person have CHD or CHD risk equivalents?*
Original NHANES Cohort 
11967 (179 million) people age 20-79 years
> 20% risk 
1898 (22 mil.) people excluded
Step 2 
Add number of risk factors
2543 (39 million) people comprised analytic cohort 
“Low risk” 
7080 (111 mil.) people excluded
Yes
No
0-1 Risk 
Factors
Step 3 
Apply Framingham model
“Moderate risk” (<10%) 
ATP III Guidelines 
Consider drug rx if LDL  ≥160  
LDL goal <130  
“Mod. high risk” (10-20%) 
ATP III Guidelines 
Consider drug rx if LDL ≥130  
(optional ≥100) 
LDL goal <130  
(optional goal <100) 
“High risk” (>20%) 
ATP III Guidelines 
Consider drug rx if LDL ≥100  
(optional ≥70) 
LDL goal <100  
(optional goal <70) 
Taking lipid-lowering drug 
(ineligible for analysis)† 
446 (7 mil.) people excluded
 2 Risk Factors
(Indeterminate Risk)
≥
Figure 1. Creation of analytic cohort and LDL treatment guidelines for patients undergoing Framingham-based risk stratification. *CHD risk
equivalents included self-report of myocardial infarction, angina pectoris, diabetes mellitus, and stroke. †Persons taking lipid-lowering drugs
ineligible for analysis. ‡CHD risk factors included: cigarette smoking, hypertension, HDL <40 mg/dl, family history of premature CHD, and age
(>45 years for men, >55 years for women). Persons with HDL >60 mg/dl had 1 point subtracted from their risk factor sum score.
1147 Gordon et al.: Point-Based vs. Equation-Based Framingham Models JGIMrisk scores above 10% as calculated by the original model
(data not shown in Table).
Figure 3 shows results from the perspective of point-based
scores. For each level of point-based risk, the box-and-
whisker format shows the distribution of risk estimates
calculated by the original model. For example, consider
women with a point-based risk estimate of 8%. The upper
border of the box corresponds to the upper 25th percentile of
risk estimates calculated by the original model. Since the
upper border of the box lies at 10% risk, approximately one-
quarter of women with point-based scores of 8% had original
model scores of 10% or above. As such, one-quarter of women
with a point-based score of 8% would be reclassified from the
“moderate risk” category (<10% risk) to the “moderately high
risk” category (10-20% risk) had the original model been used
instead. Overall, for women and men with point-based scores
above 6%, reclassification into different ATP III risk strata was
common. In contrast, very few subjects with point-based
scores of 6% or less would have been classified into the
different ATP III risk groups had the original model been used
instead of the point-based version.
Finally, we evaluated the potential impact of risk group
misclassification on guideline-recommended treatment deci-
sions. Under standard cutpoints of the original ATP III
guidelines, 25% of subjects (95% CI, 17% to 36%) misclassi-
fied by the point-based model would have had different drug
treatment strategies recommended as a result of misclassifi-
cation, with 18% (95% CI, 11%–26%) recommended for more
intensive treatment and 7% (95% CI, 4%–12%) recommended
for less intensive treatment (P=0.01 for direction of treatment
effects). Using more aggressive optional targets published in a
2004 update to ATP III, 46% of subjects (95% CI, 37% to 56%)
misclassified by the point-based model would have drug
treatment recommendations changed as a result of misclassifi-
cation, including 39% (95% CI, 31%–48%) being recommended
for more intensive therapy and 7% (95% CI, 4%–13%) for less
intensive therapy (P<0.001 for direction of treatment effects).
DISCUSSION
In this nationally representative study, the original and point-
based Framingham models produced clinically meaningful dif-
ferences in estimated CHD risk for many individuals and
stratified substantial numbers of patients into different risk
groups established by ATP III guidelines. Overall, the point-based
system classified 15% of eligible Americans (5.7 million people)
into different risk groups than the original Framingham model.
Misclassification predominantly shifted patients into higher risk
groups, with 10% of adults (3.9 million) misclassified into higher
risk groups and 5% (1.8 million) into lower risk groups, and had
the potential to impact drug treatment recommendations in 25–
46% of affected subjects not currently taking lipid-lowering
therapy. Because our analyses excluded study subjects with
incomplete data, patients on lipid-lowering therapy, and patients
who in clinical practice may receive Framingham risk prediction
outside formal guideline criteria, our results underestimate the
number of Americans potentially affected by differences in the
point-based and original Framingham models.
6
These discrepancies comprise one of the ongoing challenges
in a history of impressive advances in cardiovascular risk
assessment. Beginning with a sum-of-risk-factors approach in
the first report of the National Cholesterol Education Program,
successive advances in modeling have improved clinicians’
ability to predict—and thereby better prevent—cardiovascular
events.
15–18 As predictive models became more complex and
impractical to calculate by hand, point-based versions became
necessary to facilitate their regular use. This need may persist in
settings where computer-based risk calculators are not readily
available at the point of care, as it may be preferable to have an
imperfect system of risk prediction than none at all. However, as
the availability of desktop- and handheld-based computers has
become routine in clinical practice, there is limited need for
predictive models that can be calculated using pen and paper.
Nonetheless, the point-based system remains in widespread
use, including in risk calculators on websites and personal
digital assistants, and such tools are often not transparent in
noting which model they use. Thus, the misclassifications of
risk that we observed are likely common in clinical practice, and
may have substantial clinical and policy implications. Of
particular note, over two-thirds of misclassifications moved
patients into higher risk groups. Because guidelines recom-
mend more aggressive treatment strategies for patients in higher
risk groups, this misclassification may drive increases in the use
of lipid-lowering medications. This may have some benefits by
reducing cardiovascular event rates, although at the risk of
increasing adverse drug reactions, patients’ medication
Table 1. Characteristics of Sample
Characteristic % of sample*
Age, median (interquartile range) 48 (38–59)
Female 34%
Race
White 78%
Black 9%
Asian/PI 9%
Other 4%
Current cigarette smoker 50%
Hypertension 56%
Family history of CHD 30%
HDL <40 mg/dl 46%
LDL cholesterol (mg/dl)
<100 22%
100–129 33%
130–159 30%
≥160 15%
*N = 2,543 subjects. LDL cholesterol was assessed in 1,079 subjects
whose laboratory tests were drawn in the morning
Point-based model 
Moderate risk 
Moderately 
high risk  High risk 
Moderate risk 24.2m (63%)  3.2m (8%)  <0.1m (<1%)  27.4m (71%) 
Original 
model 
Moderately 
high risk 0.6m (2%)  7.3m (19%)  0.7m (2%)  8.6m (22%) 
High risk <0.1m (<1%)  1.2m (3%)  1.5m (4%)  2.7m (7%) 
24.8m (64%)  11.6m (30%)  2.2m (6%)  38.7m (100%)
Figure 2. Classification of Subjects into Risk Groups by the Point-
Based and Original Model. *Cells to the right of the diagonal
represent the point-based system estimating a higher risk than the
original model. Cells to the left of the diagonal represent the point-
based system estimating a lower risk than the original model.
Overall, 2,543 subjects contributed data toward this table
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19 In addition,
there is debate over the utility of expanding drug therapy
beyond NCEP guidelines.
3,20–30
Also concerning is potential undertreatment for the 1.8
million people whom the point-based system misclassifies
into lower risk groups, particularly the nearly 50% of people
(1.2 million) at high coronary risk whom the point-based
system triages into lower risk categories. Failure to define
and pursue aggressive LDL goals in such patients may
compound the widespread undertreatment of persons at high
cardiovascular risk.
10
Unfortunately, there does not appear to be a simple “fix” to
correct the misclassification that occurred under the point-
based system. Patterns of misclassification were complex,
varying by underlying CHD risk, sex, and age. In addition, the
population-level implications of misclassification also vary
among age and sex groups. For example, a substantial
majority (80%) of the 1.4 million misclassified women were
misclassified into higher risk groups, largely reflecting the
fact that most women had calculated risk of under 10% by
the original model, so their only available direction for risk
group misclassification was into a higher risk group. In
contrast, while misclassification also predominantly placed
men into higher risk groups, a substantial minority (36%)
were shifted into lower risk groups, leaving them susceptible
to undertreatment. This was particularly notable for the 2.5
Table 2. Differences in Estimated Risk by Original Framingham Model and Point-Based System, by Level of Risk
Men
Overall “Moderate risk”“ Moderately high risk”“ High risk”
Risk difference between models –
mean (SD), [range]
0.6% (3.3%) 0.9% (1.5%) 0.9% (4.1%) -1.9% (7.7%)
[-29.4% to 14.5%] [-4.4% to 10.3%] [-7.9% to 14.5%] [-29.4% to 9.7%]
Absolute risk difference between
models – median (IQR)
1.4% 1.0% 2.3% 3.6%
(0.6% to 2.9%) (0.5% to 1.8%) (1.1% to 4.7%) (1.8% to 6.4%)
Women
Overall “Moderate risk”“ Moderately high risk”“ High risk”
Risk difference between models –
mean (SD), [range]
0.4% (2.5%) 0.4% (1.7%) 1.6% (5.3%) †
[-20.2% to 12.1%] [-4.6% to 12.1%] [-7.6% to 11.6%]
Absolute risk difference between
models – median (IQR)
0.6% 0.5% 3.1% †
(0.2% to 1.7%) (0.2% to 1.4%) (1.6% to 5.3%)
*Risks bands shown at top of the table were calculated using the original model. Positive numbers in the first row (means) correspond to the point-based
system predicting higher risk than the original model; negative numbers correspond to the opposite
†Estimatesofdifferencesbetweenthetwomodelsareunreliableforwomenat>20%riskduetolownumbersofsubjectsinthisriskgroupintheNHANESsample
Figure 3. Classification of Subjects into Risk Groups by the Point-Based and Original Model. *Cells to the right of the diagonal represent the
point-based system estimating a higher risk than the original model. Cells to the left of the diagonal represent the point-based system
estimating a lower risk than the original model. Overall, 2,543 subjects contributed data toward this table
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half of whom were misclassified by the point-based model
into a lower risk group.
ATP III guidelines acknowledge that the original model
g i v e sm o r ep r e c i s ee s t i m a t e so fr i s kt h a nt h ep o i n t - b a s e do n e ,
but note that use of the point-based system “provide[s] a
result that is accurate for clinical purposes.”
31 While the
differences in predicted risk between the models are small for
the majority of patients, there are substantial numbers of
patients for whom the two models produce clinically mean-
ingful differences in predicted risk. National guidelines would
benefit from acknowledging the calculated discrepancies
between the two models and educating and guiding clinicians
about preferred methods of risk stratification. More impor-
tantly, current guidelines should strongly consider endorsing
the original model as the preferred method of risk calculation
and as the sole appropriate option for computer or PDA-
based risk calculators. In addition, patients and clinicians
who made treatment decisions based on the point-based
system should consider recalculating risk based on the
original Framingham model and where appropriate adjust
treatment plans accordingly.
Our results should be interpreted in the context of known
limitations of the original Framingham model and previous
evaluations of the NCEP risk stratification algorithm.
6,7,32
The original Framingham model has only moderate ability to
distinguish between persons who will or will not have future
coronary events (with ROC curves from validation studies
mostly in the range of 0.65 to 0.75).
33–36 This model was also
developed in a mostly white, middle-class population, and
validation studies have revealed that it overestimates CHD
risk in a number of other populations.
33–36 Other research
suggests that Framingham-based risk assessment should be
expanded to patients with 0 or 1 risk factors.
6,7 In addition,
national guidelines from other countries use versions of the
Framingham model in different, often more conservative ways
to guide lipid management.
37 In the US, it is well-documented
that many patients—particularly those at high coronary risk—
have LDL levels above current guideline recommendations.
10
Thus, our findings should be interpreted as one piece of a
larger challenge of appropriately identifying individuals’
coronary risk profiles and increasing adherence to treatment
strategies optimally tailored to those individuals’ risk.
The next generation of cholesterol guidelines (ATP IV) is
expected to be released in the near future, and it is likely that
these new guidelineswillpredictriskusinga newmodelofglobal
cardiovascular risk prediction that incorporates a broader range
of cardiovascular outcomes.
35 Nonetheless, score-sheet versions
of this model have already been developed and if applied to
guidelines may result in problems similar to those that we
observed.
35 Thus, when simplifying future models of cardiovas-
cular or other forms of risk, it will be essential to account for the
practical effects of simplification on algorithm-based manage-
ment decisions and to disseminate these analyses in peer-
reviewed publications to maximize transparency.
38
There are several limitations to our study. Our estimates of
how many subjects would be recommended for changes in lipid-
lowering therapy based on misclassification are approximate
due to limited sample sizes, absence of data on potential lifestyle
interventions, and potential inaccuracies in self-reported use of
lipid-lowering medications. In addition, we did not evaluate
users of lipid-lowering drugs, so we do not know what the
impact of using different Framingham models would have been
prior to their initiating drug treatment. Finally, our study did not
have access to actual cardiovascular outcomes, and so we are
unable to determine the accuracy of these models for predicting
cardiovascular events. Nonetheless, the original Framingham
model is the de facto gold standard for ATP III-based risk
prediction, and mathematically is it very unlikely that a point-
based system derived from the original model would be more
accurate than the original model itself.
In summary, the point-based Framingham risk prediction
tool misclassifies millions of Americans into different ATP III risk
groups compared with the original Framingham model, with 25–
46% of affected subjects experiencing potential impacts on drug
treatment recommendations. Guidelines and their associated
risk prediction tools should account for the clinically meaningful
differences that can arise between original and point-based
models and the impact that these differences can have on
treatment decisions. This will support the goal of a clinically
consistent, transparent, and standardized approach to cardio-
vascular risk assessment.
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